Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development

Alexandria University40 enrolled

Overview

Impact of Immunosuppressive Therapy for Sarcoidosis on Lymphoma Development

This is a prospective observational cohort study to be conducted in the Chest Diseases Department, Alexandria Main University Hospital. A total of 40 adult patients (≥16 years) with biopsy-proven sarcoidosis will be consecutively recruited between December 2024 and December 2025. All patients will be either newly starting or continuing immunosuppressive therapy for sarcoidosis. The treatment regimen-systemic corticosteroids, conventional steroid-sparing agents (methotrexate, azathioprine, or mycophenolate), or biologics (anti-TNF agents)-will be recorded but not altered by study design. Each patient will be followed prospectively for 12 months from enrollment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sarcoidosis Lung

Interventions

lymph node biopsyPROCEDURE

sarcoidosis diagnosis by lymph node biopsy excisiona or bronchoscopic

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Inclusion criteria include adult patients (≥18 years) with histologically confirmed sarcoidosis, receiving or planned to receive immunosuppressive therapy Exclusion Criteria:Patients with a prior history of lymphoma or other active malignancy, HIV infection, or other primary immunodeficiency will be excluded. \-

Locations (1)

Alexandria main university hospital

Alexandria, Asafra, Egypt

Outcomes

Primary Outcomes

The primary outcome will be incident, biopsy-proven lymphoma during the 12-month follow-up.

LYMPH NODE BIOPSY EITHER EXCISIONAL OR BRONCHOSCOPIC

Time frame: 12 MONTHS

lymphoma development

lymph node biopsy excisional or bronchoscopic

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.